ACADIA Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.About ACAD
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
ACAD Key Statistics
Stock Snapshot
ACADIA Pharmaceuticals(ACAD) stock is priced at $22.20, giving the company a market capitalization of 3.75B. It carries a P/E multiple of 14.52.
As of 2025-11-10, ACADIA Pharmaceuticals(ACAD) stock has fluctuated between $22.08 and $22.90. The current price stands at $22.20, placing the stock +0.5% above today's low and -3.0% off the high.
The ACADIA Pharmaceuticals(ACAD)'s current trading volume is 1.41M, compared to an average daily volume of 1.76M.
In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $26.65 and a 52-week low of $13.40.
In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $26.65 and a 52-week low of $13.40.
ACAD News
ACADIA Pharmaceuticals Inc. ( ) came out with its quarterly results last week, and we wanted to see how the business is performing and what industry forecasters...
Analyst Yigal Nochomovitz of Citi maintained a Buy rating on ACADIA Pharmaceuticals, retaining the price target of $33.00. Meet Your ETF AI Analyst Discover how...
ACADIA Pharmaceuticals Inc. ((ACAD)) has held its Q3 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks'...
Analyst ratings
65%
of 20 ratingsMore ACAD News
Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on ACADIA Pharmaceuticals and keeping the price target at $32.00. Meet Your ETF AI Analyst Dis...
Analyst Sean Laaman from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals and increased the price target to $25.00 from $24.00. Meet Your ETF A...
ACADIA Pharmaceuticals (ACAD) stock has seen steady movement recently, prompting investors to assess the latest performance trends and consider how the company’...
Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Hold rating on ACADIA Pharmaceuticals. The associated price target remains the same wit...
Needham analyst Ami Fadia maintained a Buy rating on ACADIA Pharmaceuticals today and set a price target of $29.00. Meet Your ETF AI Analyst Discover how TipRan...
Earnings Call Insights Acadia updates 2025 guidance, targets over $1B in revenue as DAYBUE and NUPLAZID reach milestone growth Nov. 06, 2025 4:36 AM ET ACADIA P...
Analyst Ritu Baral from TD Cowen maintained a Buy rating on ACADIA Pharmaceuticals and keeping the price target at $35.00. Meet Your ETF AI Analyst Discover how...